R

Regulus Therapeutics
D

RGLS

1.51000
USD
-0.11
(-6.79%)
مغلق
حجم التداول
4,365
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
98,905,202
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARWR
    -1.900
    (-8.54%)
    20.340 USD
    A
    AXSM
    -2.710
    (-2.90%)
    90.720 USD
    C
    CRSP
    -3.490
    (-7.83%)
    41.110 USD
    D
    DVAX
    -0.130
    (-1.01%)
    12.760 USD
    E
    EDIT
    -0.17500
    (-11.51%)
    1.34500 USD
    F
    FOLD
    -0.31000
    (-3.14%)
    9.57000 USD
    I
    IONS
    -1.430
    (-3.79%)
    36.260 USD
    S
    SRPT
    -5.630
    (-4.47%)
    120.200 USD
    V
    VKTX
    -8.495
    (-18.18%)
    38.230 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    المزيد
الأخبار

العنوان: Regulus Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.